Search

Your search keyword '"GÜMÜŞ, MAHMUT"' showing total 176 results
Start Over Author "GÜMÜŞ, MAHMUT"
176 results on '"GÜMÜŞ, MAHMUT"'

1. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzafer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Erul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan

Published
2023
Full Text
View/download PDF

2. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Karacin, Cengiz, Oksuzoglu, Berna, Demirci, Ayşe, Keskinkılıç, Merve, Baytemür, Naziyet Köse, Yılmaz, Funda, Selvi, Oğuzhan, Erdem, Dilek, Avşar, Esin, Paksoy, Nail, Demir, Necla, Göksu, Sema Sezgin, Türker, Sema, Bayram, Ertuğrul, Çelebi, Abdüssamet, Yılmaz, Hatice, Kuzu, Ömer Faruk, Kahraman, Seda, Gökmen, İvo, Sakin, Abdullah, Alkan, Ali, Nayır, Erdinç, Uğraklı, Muzaffer, Acar, Ömer, Ertürk, İsmail, Demir, Hacer, Aslan, Ferit, Sönmez, Özlem, Korkmaz, Taner, Celayir, Özde Melisa, Karadağ, İbrahim, Kayıkçıoğlu, Erkan, Şakalar, Teoman, Öktem, İlker Nihat, Eren, Tülay, Urul, Enes, Mocan, Eda Eylemer, Kalkan, Ziya, Yıldırım, Nilgün, Ergün, Yakup, Akagündüz, Baran, Karakaya, Serdar, Kut, Engin, Teker, Fatih, Demirel, Burçin Çakan, Karaboyun, Kubilay, Almuradova, Elvina, Ünal, Olçun Ümit, Oyman, Abdilkerim, Işık, Deniz, Okutur, Kerem, Öztosun, Buğra, Gülbağcı, Burcu Belen, Kalender, Mehmet Emin, Şahin, Elif, Seyyar, Mustafa, Özdemir, Özlem, Selçukbiricik, Fatih, Kanıtez, Metin, Dede, İsa, Gümüş, Mahmut, Gökmen, Erhan, Yaren, Arzu, Menekşe, Serkan, Ebinç, Senar, Aksoy, Sercan, İmamoğlu, Gökşen İnanç, Altınbaş, Mustafa, Çetin, Bülent, Uluç, Başak Oyan, Er, Özlem, Karadurmuş, Nuri, Erdoğan, Atike Pınar, Artaç, Mehmet, Tanrıverdi, Özgür, Çiçin, İrfan, Şendur, Mehmet Ali Nahit, Oktay, Esin, Bayoğlu, İbrahim Vedat, Paydaş, Semra, Aydıner, Adnan, Salim, Derya Kıvrak, Geredeli, Çağlayan, Yavuzşen, Tuğba, Doğan, Mutlu, and Hacıbekiroğlu, İlhan

Published
2023
Full Text
View/download PDF

3. Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Author

Kim, Hye Ryun, Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Santorelli, Melissa L., Pietanza, M. Catherine, and Rudin, Charles M.

Published
2023
Full Text
View/download PDF

4. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Author

Özgüroğlu, Mustafa, Kilickap, Saadettin, Sezer, Ahmet, Gümüş, Mahmut, Bondarenko, Igor, Gogishvili, Miranda, Nechaeva, Marina, Schenker, Michael, Cicin, Irfan, Ho, Gwo Fuang, Kulyaba, Yaroslav, Zyuhal, Kasimova, Scheusan, Roxana-Ioana, Garassino, Marina Chiara, He, Xuanyao, Kaul, Manika, Okoye, Emmanuel, Li, Yuntong, Li, Siyu, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, and Rietschel, Petra

Published
2023
Full Text
View/download PDF

5. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, and Lorusso, Domenica

Published
2023
Full Text
View/download PDF

8. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.

Author

Aygen, Bilgehan, Demir, Ahmet Muzaffer, Gümüş, Mahmut, Karabay, Oğuz, Kaymakoğlu, Sabahattin, Köksal, Aydın Şeref, Köksal, İftihar, Örmeci, Necati, and Tabak, Fehmi

Subjects
Humans, Hepatitis B virus, Hepatitis B, Immunosuppressive Agents, Antiviral Agents, Risk Factors, Consensus, Virus Activation, Turkey, Health Services, Hepatitis, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Hepatitis - B, Emerging Infectious Diseases, Liver Disease, Infectious Diseases, Clinical Research, Good Health and Well Being, Gastroenterology & Hepatology
Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.

Published
2018

9. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Author

Powles, Thomas, primary, Valderrama, Begoña P., additional, Gupta, Shilpa, additional, Bedke, Jens, additional, Kikuchi, Eiji, additional, Hoffman-Censits, Jean, additional, Iyer, Gopa, additional, Vulsteke, Christof, additional, Park, Se Hoon, additional, Shin, Sang Joon, additional, Castellano, Daniel, additional, Fornarini, Giuseppe, additional, Li, Jian-Ri, additional, Gümüş, Mahmut, additional, Mar, Nataliya, additional, Loriot, Yohann, additional, Fléchon, Aude, additional, Duran, Ignacio, additional, Drakaki, Alexandra, additional, Narayanan, Sujata, additional, Yu, Xuesong, additional, Gorla, Seema, additional, Homet Moreno, Blanca, additional, and van der Heijden, Michiel S., additional

Published
2024
Full Text
View/download PDF

11. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Author

Tewari, Krishnansu S., primary, Colombo, Nicoletta, additional, Monk, Bradley J., additional, Dubot, Coraline, additional, Cáceres, M. Valeria, additional, Hasegawa, Kosei, additional, Shapira-Frommer, Ronnie, additional, Salman, Pamela, additional, Yañez, Eduardo, additional, Gümüş, Mahmut, additional, Olivera Hurtado de Mendoza, Mivael, additional, Samouëlian, Vanessa, additional, Castonguay, Vincent, additional, Arkhipov, Alexander, additional, Tekin, Cumhur, additional, Li, Kan, additional, Toker, Sarper, additional, Keefe, Stephen M., additional, and Lorusso, Domenica, additional

Published
2024
Full Text
View/download PDF

12. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Author

Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S., Salman, Pamela, Usta, Edwin Hoyos, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M., and Monk, Bradley J.

Published
2022
Full Text
View/download PDF

13. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Author

Ünal, Çağlar, primary, Azizy, Abdulmunir, additional, Karabulut, Senem, additional, Taştekin, Didem, additional, Akyıldız, Arif, additional, Yaşar, Serkan, additional, Yalçın, Şuayib, additional, Çoban, Eyüp, additional, Evrensel, Türkkan, additional, Kalkan, Ziya, additional, Oruç, Zeynep, additional, Derin, Sümeyra, additional, Turna, Zeynep Hande, additional, Bayram, Doğan, additional, Köş, Fahriye Tuğba, additional, Şendur, Mehmet Ali Nihat, additional, Sever, Nadiye, additional, Ercelep, Özlem, additional, Seyyar, Mustafa, additional, Kefeli, Umut, additional, Uygun, Kazım, additional, Özçelik, Melike, additional, Ön, Sercan, additional, Şanlı, Ulus Ali, additional, Canaslan, Kübra, additional, Ünek, İlkay Tuba, additional, Yücel, Kadriye Bir, additional, Özdemir, Nuriye, additional, Yazıcı, Ozan, additional, Güzel, Halil Göksel, additional, Salim, Derya Kıvrak, additional, Göksu, Sema Sezgin, additional, Tatlı, Ali Murat, additional, Ordu, Çetin, additional, Selvi, Oğuzhan, additional, Sakin, Abdullah, additional, Büyükbayram, Mehmet Emin, additional, Dursun, Bengü, additional, Ürün, Yüksel, additional, Arak, Hacı, additional, Ağdaş, Gözde, additional, Uğraklı, Muzaffer, additional, Hendem, Engin, additional, Eryılmaz, Melek Karakurt, additional, Bilgin, Burak, additional, Topçu, Atakan, additional, Şimşek, Melih, additional, Büyükşimşek, Mahmut, additional, Akay, Büşra, additional, Erdal, Gülçin Şahingöz, additional, Karataş, Fatih, additional, Alan, Özkan, additional, Çağlayan, Melek, additional, Kahvecioğlu, Fatma Akdağ, additional, Demirci, Ayşe, additional, Paksoy, Nail, additional, Çetin, Bülent, additional, Gümüş, Mahmut, additional, Ak, Naziye, additional, Aydınalp, Yasemin, additional, Paydaş, Semra, additional, Güven, Deniz Can, additional, Kılıçkap, Saadettin, additional, and Sağlam, Sezer, additional

Published
2023
Full Text
View/download PDF

14. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.

Author

Monk, Bradley J., Colombo, Nicoletta, Tewari, Krishnansu S., Dubot, Coraline, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Keefe, Stephen M., and Lorusso, Domenica

Published
2023
Full Text
View/download PDF

15. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Author

Novello, Silvia, primary, Kowalski, Dariusz M., additional, Luft, Alexander, additional, Gümüş, Mahmut, additional, Vicente, David, additional, Mazières, Julien, additional, Rodríguez-Cid, Jeronimo, additional, Tafreshi, Ali, additional, Cheng, Ying, additional, Lee, Ki Hyeong, additional, Golf, Alexander, additional, Sugawara, Shunichi, additional, Robinson, Andrew G., additional, Halmos, Balazs, additional, Jensen, Erin, additional, Schwarzenberger, Paul, additional, Pietanza, M. Catherine, additional, and Paz-Ares, Luis, additional

Published
2023
Full Text
View/download PDF

17. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Monk, B, Tewari, K, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yañez, E, Gümüş, M, Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Martin Nguyen, A, Monberg, M, Colombo, N, Lorusso, D, Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, Lorusso, Domenica, Monk, B, Tewari, K, Dubot, C, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yañez, E, Gümüş, M, Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Martin Nguyen, A, Monberg, M, Colombo, N, Lorusso, D, Monk, Bradley J, Tewari, Krishnansu S, Dubot, Coraline, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Salman, Pamela, Yañez, Eduardo, Gümüş, Mahmut, Hurtado de Mendoza, Mivael Olivera, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Tekin, Cumhur, Li, Kan, Martin Nguyen, Allison, Monberg, Matthew J, Colombo, Nicoletta, and Lorusso, Domenica

Abstract

Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus chemotherapy with or without bevacizumab, with manageable toxicity, in patients with persistent, recurrent, or metastatic cervical cancer. In this Article, we report patient-reported outcomes (PROs) from KEYNOTE-826. Methods: KEYNOTE-826 is a multicentre, randomised, phase 3 trial in 151 cancer treatment centres in 19 countries. Eligible patients were aged 18 years or older with persistent, recurrent, or metastatic cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemotherapy was allowed) and not amenable to curative treatment and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1) centrally by means of an interactive voice response system in a double-blind manner to receive either pembrolizumab 200 mg or placebo every 3 weeks intravenously for up to 35 cycles plus chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin area under the curve 5 mg/mL per min, intravenously) with or without bevacizumab 15 mg/kg every 3 weeks intravenously. Randomisation (block size of 4) was stratified by metastatic disease at diagnosis, planned bevacizumab use, and PD-L1 combined positive score. Patients, investigators, and other study personnel involved in study treatment administration or clinical evaluation of patients were unaware of treatment group assignments. PRO instruments were the EORTC Quality-of-Life-Core 30 (QLQ-C30), the EORTC cervical cancer module (QLQ-CX24), and the EuroQol-5 dimension-5 level (EQ-5D-5L) visual analogue scale, each collected before treatment at cycles 1–14 and every other cycle thereafter. Primary endpoints were overall survival and progression-free survival per RECIST version 1.1 by investigator

Published
2023

18. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Author

Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, School of Medicine, Selçukbiricik, Fatih (ORCID 0000-0002-1273-1674 & YÖK ID 202015), Karacin, Cengiz; Oksuzoglu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah; Alkan, Ali; Nayır, Erdinç; Uğraklı, Muzaffer; Acar, Ömer; Ertürk, İsmail; Demir, Hacer; Aslan, Ferit; Sönmez, Özlem; Korkmaz, Taner; Celayir, Özde Melisa; Karadağ, İbrahim; Kayıkçıoğlu, Erkan; Şakalar, Teoman; Öktem, İlker Nihat; Eren, Tülay; Urul, Enes; Mocan, Eda Eylemer; Kalkan, Ziya; Yıldırım, Nilgün; Ergün, Yakup; Akagündüz, Baran; Karakaya, Serdar; Kut, Engin; Teker, Fatih; Demirel, Burçin Çakan; Karaboyun, Kubilay; Almuradova, Elvina; Ünal, Olçun Ümit; Oyman, Abdilkerim; Işık, Deniz; Okutur, Kerem; Öztosun, Buğra; Gülbağcı, Burcu Belen; Kalender, Mehmet Emin; Şahin, Elif; Seyyar, Mustafa; Özdemir, Özlem; Kanıtez, Metin; Dede, İsa; Gümüş, Mahmut; Gökmen, Erhan; Yaren, Arzu; Menekşe, Serkan; Ebinç, Senar; Aksoy, Sercan; İmamoğlu, Gökşen İnanç; Altınbaş, Mustafa; Çetin, Bülent; Uluç, Başak Oyan; Er, Özlem; Karadurmuş, Nuri; Erdoğan, Atike Pınar; Artaç, Mehmet; Tanrıverdi, Özgür; Çiçin, İrfan; Şendur, Mehmet Ali Nahit; Oktay, Esin; Bayoğlu, İbrahim Vedat; Paydaş, Semra; Aydıner, Adnan; Salim, Derya Kıvrak; Geredeli, Çağlayan; Yavuzşen, Tuğba; Doğan, Mutlu; Hacıbekiroğlu, İlhan, and School of Medicine

Abstract

Background: there is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: a total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: the median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that be, NA

Published
2023

21. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Author

Gümüş, Mahmut, primary, Chen, Chieh‐I, additional, Ivanescu, Cristina, additional, Kilickap, Saadettin, additional, Bondarenko, Igor, additional, Özgüroğlu, Mustafa, additional, Gogishvili, Miranda, additional, Turk, Haci M., additional, Cicin, Irfan, additional, Harnett, James, additional, Mastey, Vera, additional, Naumann, Ulrike, additional, Reaney, Matthew, additional, Konidaris, Gerasimos, additional, Sasane, Medha, additional, Brady, Keri J. S., additional, Li, Siyu, additional, Gullo, Giuseppe, additional, Rietschel, Petra, additional, and Sezer, Ahmet, additional

Published
2022
Full Text
View/download PDF

23. Retrospective evaluation of premenopausal hormone‐sensitive breast cancer patients treated with adjuvant gonadotropin‐releasing hormone analogue: Anatolian Society of Medical Oncology (ASMO) study

Author

Demirci, Ayşe, Alkış, Necati, Dane, Faysal, Durnalı, Ayşe, Yazıcı, Ömer Kamil, Rzayev, Rashad, Kaya, Serap, Yazılıtaş, Doğan, İnanç, Mevlüde, Özçelik, Melike, Akman, Tülay, Kaplan, Mehmet Ali, Günaydın, Yusuf, Ulaş, Arife, Sönmez, Özlem, Tokluoğlu, Saadet, Gököz Doğu, Gamze, Bal, Öznur, and Gümüş, Mahmut

Published
2018
Full Text
View/download PDF

24. Meme kanserinde neoadjuvan kemoterapi yanıtlarını öngörmede belirleyici olarak açlık kan şekeri ve vücut kitle indeksi

Author

DÜLGAR, Özgecan, AY, Seval, and GÜMÜŞ, Mahmut

Subjects
Blood glucose, breast cancer, neoadjuvant therapy, Kan şekeri, meme kanseri, neoadjuvan tedavi, Health Care Sciences and Services, Sağlık Bilimleri ve Hizmetleri
Abstract

Aim: Obesity is a well-known modifiable risk factor for breast cancer. Impaired fasting glucose is a component of metabolic syndrome and a significant risk for diabetes. We aimed to research the effect of these two major components of metabolic syndrome on neoadjuvant chemotherapy (NAC) response in breast cancer.Methods: We conducted 161 patients who had received NAC from January 2016 to January 2022. Fasting plasma glucose levels were measured at least two times and BMI was recorded before starting NAC. Impaired fasting glucose is defined as plasma glucose levels of 100 to 125 mg per dL. Analyses were compared into two groups according to FPG levels below or above 100 mg/dl and according to BMI obese (BMI30≥ kg/m2), or non-obese (BMI, Amaç: Obezite, meme kanseri gelişiminde etkili olabilen değiştirilebilir bir risk faktörüdür. Bozulmuş açlık glikozu ise metabolik sendromun bir bileşenidir ve diyabet gelişimi için önemli bir risk faktörüdür. Metabolik sendromun bu iki ana bileşeninin meme kanserinde neoadjuvan kemoterapi (NAK) yanıtı üzerindeki etkisini araştırmayı amaçladık.Yöntemler: Ocak 2016’dan Ocak 2022’ye kadar NAK alan 161 meme kanseri hastasını geriye dönük olarak inceledik. Açlık plazma glukoz (APG) seviyeleri en az iki kez ölçüldü ve NAK’a başlamadan önceki vücut kitle indeksileri (VKİ) kaydedildi. Bozulmuş açlık glukozu, 100 ile 125 mg/dl plazma glukoz seviyeleri olarak tanımlandı. Analizler, APG seviyelerine göre 100 mg/dl’nin altındaki ve üzerindeki veya VKİ'ye göre obez (VKİ 30≥ kg/m2) ve obez olmayan (VKİ

Published
2022

25. First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis

Author

Isikdogan, A., Sakin, A., Tural, D., Cubukcu, E., Bozkurt, O., Harputluoglu, H., Kefeli, U., Alacacioglu, A., Geredeli, C., Cicin, I., Artac, M., Karabulut, B., Sendur, M., Bilir, C., Turk, H., YALÇIN, SIDDIKA SONGÜL, GÜMÜŞ, MAHMUT, Karadurmus, N., Arslan, C., Cevik, D., Dane, F., Cil, T., and KÖKER, İBRAHİM HAKKI

Subjects
Onco-colon Turkey study subgroup analysis-, ANNALS OF ONCOLOGY, cilt.33, 2022 [Isikdogan A., Turk H., Bilir C., Sendur M., Karabulut B., Artac M., Cicin I., Geredeli C., Alacacioglu A., Kefeli U., et al., -First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer]
Published
2022

26. Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Author

Artaç, Mehmet, Çubukçu, Erdem, Bozkurt, Oktay, Bilici, Ahmet, Çelik, S., Özçelik, M., Öven, B., Şimşek, E., Geredeli, C., Karaca, M., Cil, T., Harputluoğlu, Hakan, Şendur, Mehmet Ali Nahit, Türk, H. Mehmet, Kefeli, Umut, Alacacıoğlu, Ahmet, Tural, D., Sakin, A., Karadurmuş, Nuri, Çevik, Duygu, Dane, Faysal, Gümüş, Mahmut, and ATASOY, SEZEN

Subjects
Chemotherapy, A multicenter Onco-Colon Turkey study-, ANNALS OF ONCOLOGY, cilt.33, 2022 [Artac M., Cubukcu E., Bozkurt O., Bilici A., Celik S., Ozcelik M., Oven B., Simsek E., Geredeli C., Karaca M., et al., -Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC)], Metastatic Colon Cancer (mCRC), Onco-Colon Turkey Study
Abstract

Background: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim was to study the real-life experience (onco-colon registry Turkey) of maintenance chemotherapy with antiEGFR or antiVEGF mAbs after the standart firstline doublet chemotherapy backbone in RAS wild-type mCRC patients. Amgen

Published
2022

27. Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023)

Author

Monk, Bradley, primary, Tewari, Krishnansu, additional, Dubot, Coraline, additional, Caceres, M. Valeria, additional, Hasegawa, Kosei, additional, Shapira-Frommer, Ronnie, additional, Salman, Pamela, additional, YANEZ, EDUARDO, additional, Gümüş, Mahmut, additional, de Mendoza, Mivael Olivera Hurtado, additional, Samouëlian, Vanessa, additional, Castonguay, Vincent, additional, Arkhipov, Alexander, additional, Tekin, Cumhur, additional, Li, Kan, additional, Nguyen, Allison Martin, additional, Monberg, Matthew, additional, Colombo, Nicoletta, additional, and Lorusso, Domenica, additional

Published
2022
Full Text
View/download PDF

28. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?

Author

Dülgar, Özgecan, primary, Öven, Başak Bala, additional, Atcı, Muhammed Mustafa, additional, Arıkan, Rukiye, additional, Ay, Seval, additional, Ayhan, Murat, additional, Selvi, Oğuzhan, additional, Ozyukseler, Deniz Tataroglu, additional, Bayram, Ertuğrul, additional, Özcan, Erkan, additional, Yasin, Ayşe İrem, additional, and Gümüş, Mahmut, additional

Published
2022
Full Text
View/download PDF

29. CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

Author

Özgüroğlu, Mustafa, primary, Sezer, Ahmet, additional, Kilickap, Saadettin, additional, Gümüş, Mahmut, additional, Bondarenko, Igor, additional, Gogishvili, Miranda, additional, He, Xuanyao, additional, McGinniss, Jennifer, additional, Gullo, Giuseppe, additional, Rietschel, Petra, additional, and Quek, Ruben GW, additional

Published
2022
Full Text
View/download PDF

30. CLO22-050: Hospitalization and Supportive Care Medication (SCM) Utilization in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) in EMPOWER-Lung 1

Author

Gümüş, Mahmut, primary, Sezer, Ahmet, additional, Yan, Eric, additional, Kilickap, Saadettin, additional, Bondarenko, Igor, additional, Özgüroğlu, Mustafa, additional, Gogishvili, Miranda, additional, Gullo, Giuseppe, additional, Rietschel, Petra, additional, and GW Quek, Ruben, additional

Published
2022
Full Text
View/download PDF

31. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

Author

Yasin, Ayse Irem, primary, Aydin, Sabin Göktas, additional, Sümbül, Bilge, additional, Koral, Lokman, additional, Şimşek, Melih, additional, Geredeli, Çağlayan, additional, Öztürk, Akın, additional, Perkin, Perihan, additional, Demirtaş, Derya, additional, Erdemoglu, Engin, additional, Hacıbekiroglu, İlhan, additional, Çakır, Emre, additional, Tanrıkulu, Eda, additional, Çoban, Ezgi, additional, Ozcelik, Melike, additional, Çelik, Sinemis, additional, Teker, Fatih, additional, Aksoy, Asude, additional, Fırat, Sedat T, additional, Tekin, Ömer, additional, Kalkan, Ziya, additional, Türken, Orhan, additional, Oven, Bala B, additional, Dane, Faysal, additional, Bilici, Ahmet, additional, Isıkdogan, Abdurrahman, additional, Seker, Mesut, additional, Türk, Hacı M, additional, and Gümüş, Mahmut, additional

Published
2022
Full Text
View/download PDF

32. Surgical, pathological and clinical features of advanced collorectal cancers with metastasectomy. 'Onco-Colon Turkey Registry' real-life data

Author

Karadurmuş, Nuri, Yıldırım, Emre, Yalçın, Şuayib, Gümüş, Mahmut, Bilir, Cemil, Çubukçu, Erdem, Tanrıkulu Şimşek, Eda, Arslan, Çağatay, Dane, Faysal, Çelik, Sinemiş, Bilici, Ahmet, Şendur, Mehmet Ali Nahit, Öven, Başak Bala, Işıkdoğan, Abdurrahman, Türk, Hacı Mehmet, Karaca, Mustafa, Karabulut, Bülent, Özçelik, Melike, Çevik, Duygu, and Kefeli, Umut

Subjects
Metastasectomy, Collorectal Cancers, Onco-Colon Turkey Registry
Abstract

Background: The contribution of metastasectomy to progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced stage colorectal cancer has been demonstrated in clinical trials. However, clinical trials may not represent the efficacy of treatment given to the whole population in daily practice, therefore evaluation of real-life data is needed. Methods: The demographic, pathological and clinical characteristics of 1064 RAS wild type pts were recorded in 28 centers in Turkey between January 2016 and March 2019 as part of the Onco-Colon Registry Program (NCT04757311). Metastasectomy was performed in 169 patients (15.9%). In this study, pts with and without metastasectomy were compared in terms of demographic, histopathological and clinical features and treatment results. Results: Median follow-up time was 24 months(mos) (1-74), median age was 59 years (30-81). 32.5% of the pts were women. The proportion of pts with primary right colon was determined to be 16.8%. Synchronous metastasis was detected in 76.3% of those who underwent metastasectomy. Isolated liver metastasectomy was performed in 85.8% of the pts. It has been shown that 21.1% of the pts have MSI-H and 23.3% have a mucinous component. Metastasectomy was performed after conversion therapy in 54.8% of pts. In the patient group who underwent metastasectomy after medical treatment, the median time between the beginning of treatment and metastasectomy was found to be 7 mos (2-34). When the patient characteristics were compared, no significant difference was found between the groups with and without metastasectomy (p > 0.05). The median PFS (mPFS) was 13.5 mos in the group that underwent metastasectomy and 9.9 mos in the group that was not performed (p < 0.0001; HR: 0.63 (95% CI: 0.51-0.77). The median OS (mOS) was 47.3 mos in the group that underwent metastasectomy and 24.3 mos in the group without metastasectomy (p < 0.0001; HR: 0.36 (95% CI: 0.27-0.48). Conclusions: The significant contribution of metastasectomy on mPFS and mOS was shown in this reallife data based trial, where no difference was found in terms of general participation characteristics. In daily practice, prolonged mPFS and mOS emerges as pts who are followed-up radiologically at regular intervals from the beginning and who are appropriate for surgery have the chance of metastasectomy.

Published
2022

33. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

Author

Ay, Seval, primary, Atcı, Muhammed Mustafa, additional, Arıkan, Rukiye, additional, Dülgar, Özgecan, additional, Özyükseler, Deniz Tataroğlu, additional, Paksoy, Nail, additional, Doğan, İzzet, additional, Öztosun, Buğra, additional, Taştekin, Didem, additional, Öven, Başak Bala, additional, and Gümüş, Mahmut, additional

Published
2022
Full Text
View/download PDF

34. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Author

Clingan, P., Rietschel, P., Gladkov, O., Sriuranpong, V., Gullo, G., Lowy, I., Seebach, F., Lee, S., Pouliot, J., Mcginniss, J., Rizvi, N., Bondarenko, I., Sezer, A., Kilickap, S., GÜMÜŞ, MAHMUT, ÖZGÜROĞLU, Mustafa, Gogishvili, M., Turk, H. M., Cicin, I., and Bentsion, D.

Subjects
Subgroup Analysis from EMPOWER-Lung 1-, JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 [Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., ÖZGÜROĞLU M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC]
Published
2021

35. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Author

Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony, Mezni, Essia, Evans, Catherine Karine, Chinot, Olivier, Loschi, Alain, Arnaud, Sylvie, Mellinas, Marie, Bay, Jacques-Olivier, Bouleuc, Carole, Firmin, Nelly, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Penel, Nicolas, Rodrigues, Manuel, Thiery-Vuillemin, Antoine, Wislez, Marie, L’allemain, Gilles, Robert, Jacques, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen, Monk, Bradley, Oaknin, Ana, Tinker, Anna, Gilbert, Lucy, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, de Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, de La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, Rousset-Rouviere, Sandrine, Rochigneux, Philippe, Chrétien, Anne-Sophie, Fattori, Stéphane, Gorvel, Laurent, Provansal, Magali, Lambaudie, Eric, Olive, Daniel, Martin, Johan, Guérin, Mathilde, Monneur, Audrey, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Bidard, François-Clément, Mari, Roxane, Narducci, Fabrice, Cappiello, Maria-Antonietta, Rousseau, Fréderique, Blache, Guillaume, Birnbaum, Daniel, Cropet, C., Montegut, C., Frindte, J., Cinieri, S., Guerra-Alia, E.M., Bogner, G., Yoshida, H., Vergote, I., Hietanen, S., Largillier, R., Canzler, U., Gratet, A., Marmé, F., Pujade-Lauraine, E., Favier, L., Ray-Coquard, I.L., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, First line, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, medicine.disease, Olaparib, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, business, Ovarian cancer, medicine.drug
Abstract

International audience; 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884.

Published
2021

36. Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study.

Author

Gümüş, Mahmut, Chen, Chieh‐I, Ivanescu, Cristina, Kilickap, Saadettin, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Harnett, James, Mastey, Vera, Naumann, Ulrike, Reaney, Matthew, Konidaris, Gerasimos, Sasane, Medha, Brady, Keri J. S., Li, Siyu, Gullo, Giuseppe, Rietschel, Petra, and Sezer, Ahmet

Subjects
*NON-small-cell lung carcinoma, *CEMIPLIMAB, *COUGH, *PATIENT reported outcome measures, *PROGRAMMED death-ligand 1, *CLINICAL trials
Abstract

Background: In the EMPOWER‐Lung 1 trial (ClinicalTrials.gov, NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed cell death‐ligand 1 (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among trial participants. Methods: Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350 mg every 3 weeks or platinum‐doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life‐Core 30 (QLQ‐C30) and Lung Cancer Module (QLQ‐LC13) questionnaires. Mixed‐model repeated measures analysis estimated overall change from baseline for PD‐L1 ≥50% and intention‐to‐treat populations. Kaplan–Meier analysis estimated time to definitive deterioration. Results: In PD‐L1 ≥50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ‐C30 and QLQ‐LC13 scores showed moderate‐to‐high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status/quality of life (GHS/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32‐0.71) to 0.63 (95% CI, 0.41‐0.96). Cemiplimab showed lower risk of definitive deterioration for disease‐related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment‐related symptoms (peripheral neuropathy, alopecia, nausea/vomiting, appetite loss, constipation, diarrhea) (nominal p <.05). Results were similar in the intention‐to‐treat population. Conclusions: Results support cemiplimab for first‐line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum‐doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden. This analysis from a phase 3 clinical trial in patients with advanced non–small cell lung cancer showed that improved survival with cemiplimab was accompanied by significant benefits relative to chemotherapy in patient‐reported global health status/quality of life and functioning. Patients treated with cemiplimab also reported a reduction in symptom burden for key disease‐related symptoms and symptoms generally associated with chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Author

Colombo, Nicoletta, primary, Dubot, Coraline, additional, Lorusso, Domenica, additional, Caceres, M. Valeria, additional, Hasegawa, Kosei, additional, Shapira-Frommer, Ronnie, additional, Tewari, Krishnansu S., additional, Salman, Pamela, additional, Hoyos Usta, Edwin, additional, Yañez, Eduardo, additional, Gümüş, Mahmut, additional, Olivera Hurtado de Mendoza, Mivael, additional, Samouëlian, Vanessa, additional, Castonguay, Vincent, additional, Arkhipov, Alexander, additional, Toker, Sarper, additional, Li, Kan, additional, Keefe, Stephen M., additional, and Monk, Bradley J., additional

Published
2021
Full Text
View/download PDF

39. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wi̇ld-type patients treated with biologics second-line mCRC

Author

Yıldırım, Mahmut Emre, Karaca, Mustafa, Artaç, Mehmet, Çiçin, İrfan, Geredeli, Çağlayan, Alacacıoğlu, Ahmet, Tanrıkulu Şimşek, Eda, Bilici, Ahmet, Harputluoğlu, Hakan, Özçelik, Melike, Bozkurt, Oktay, Yüksel, Sinemiş, Tural, Deniz, Sakin, Abdullah, Çil, Timuçin, Öven, Bala Başak, Dane, Faysal, Çevik, Duygu, Gümüş, Mahmut, and Işıkdogan, Abdurrahman

Subjects
Cancer Research, Oncology, Biologics Second-Line mCRC, Onco-colon Turkey Registry, Treatment Outcomes From
Abstract

e15562 Background: Varieties of systemic treatments in second-line treatment for metastatic colorectal cancer (mCRC) patients have showed an improvement on survival. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. Therefore, we aimed to investigate second-line treatment selection in patients with RAS-wild type mCRC. Methods: Medical records from 28 centers were collected for patients diagnosed with RAS wild-type and were included into the study. Histopathological, molecular and clinical characteristics of the patients were recorded. The treatment duration, response rate, progression-free survival and safety results were determined. Patients were compared according to the second-line biological treatments as anti-EGFR group (Group A and B; panitumumab and cetuximab) and anti-VEGF group (group C; bevacizumab or aflibercept). Results: A total of 1064 patients with documented RAS wild-type status were evaluated. Fifty-six percent of all first line patients were treated with regimen including biologics received second line treatment. Median age was 60 years. 34,7 percent of the patients were female. Nineteen percent of the patients had a right-sided colon tumor. 16,3 %, 22,5% and 61,2 % of all second-line patients were treated with regimen including panitumumab, cetuximab and anti-VEGF, respectively. Patients received median 5 (1-21) cycles of treatment. Also, responded patients received median 4 (1-23) cycles of treatment as maintenance treatment with biologics plus fluoropyrimidine. Overall response rate was 28,5 % for all patients. Disease control rate also was 70,6 %. The median OS was 15,7, 14,3, and 14,7 months in A, B and C group respectively (p = 0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/ aflibercept were 7,8, 6,6 and 7,4 months respectively (p = 0.848). There was not found as independent prognostic factors in multivariate analysis. Conclusions: According to the results of our real-life data study, there is no significant difference in efficacy between the combinations of biological agent and chemotherapy used in the second-line treatments. Therefore, the results of the first-line treatment become important and the use of the most effective agent at this setting also increases survival.

Published
2022

40. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Author

Colombo, N, Dubot, C, Lorusso, D, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Tewari, K, Salman, P, Hoyos Usta, E, Yañez, E, Gümüş, M, Olivera Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Toker, S, Li, K, Keefe, S, Monk, B, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, Monk, Bradley J, Colombo, N, Dubot, C, Lorusso, D, Caceres, M, Hasegawa, K, Shapira-Frommer, R, Tewari, K, Salman, P, Hoyos Usta, E, Yañez, E, Gümüş, M, Olivera Hurtado de Mendoza, M, Samouëlian, V, Castonguay, V, Arkhipov, A, Toker, S, Li, K, Keefe, S, Monk, B, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu S, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen M, and Monk, Bradley J

Abstract

BACKGROUND Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive metastatic or unresectable cervical cancer that has progressed during chemotherapy. We assessed the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab. METHODS In a double-blind, phase 3 trial, we randomly assigned patients with persistent, recurrent, or metastatic cervical cancer in a 1:1 ratio to receive pembrolizumab (200 mg) or placebo every 3 weeks for up to 35 cycles plus platinum-based chemotherapy and, per investigator discretion, bevacizumab. The dual primary end points were progression-free survival and overall survival, each tested sequentially in patients with a PD-L1 combined positive score of 1 or more, in the intention-to-treat population, and in patients with a PD-L1 combined positive score of 10 or more. The combined positive score is defined as the number of PD-L1–staining cells divided by the total number of viable tumor cells, multiplied by 100. All results are from the protocol-specified first interim analysis. RESULTS In 548 patients with a PD-L1 combined positive score of 1 or more, median progression-free survival was 10.4 months in the pembrolizumab group and 8.2 months in the placebo group (hazard ratio for disease progression or death, 0.62; 95% confidence interval [CI], 0.50 to 0.77; P<0.001). In 617 patients in the intention-to-treat population, progression-free survival was 10.4 months and 8.2 months, respectively (hazard ratio, 0.65; 95% CI, 0.53 to 0.79; P<0.001). In 317 patients with a PD-L1 combined positive score of 10 or more, progression-free survival was 10.4 months and 8.1 months, respectively (hazard ratio, 0.58; 95% CI, 0.44 to 0.77; P<0.001). Overall survival at 24 months was 53.0% in the pembrolizumab group and 41.7% in the placebo group (hazard ratio for death, 0.64; 95% CI, 0.50 to 0.81; P<0.001), 50.4% and 40.4% (hazard ratio, 0.67; 95% CI, 0.54 to 0.84; P<0.001), and 54.4% and 44.6% (hazar

Published
2021

41. Outcome of non-metastatic male breast cancer: 118 patients

Author

Arslan, Ülkü Yalçıntaş, Öksüzoğlu, Berna, Özdemir, Nuriye, Aksoy, Sercan, Alkış, Necati, Gök, Ayşe, Kaplan, Mehmet Ali, Gümüş, Mahmut, Berk, Veli, Uncu, Doğan, Baykara, Meltem, Çolak, Dilşen, Üyetürk, Ümmügül, Türker, İbrahim, and Işıkdoğan, Abdurrahman

Published
2012
Full Text
View/download PDF

43. Ebeveynlerin sosyal görünüş kaygı düzeylerine göre çocuklarının sosyal görünüşleri ile ilgili tutum ve davranış farklılıkları.

Author

Gümüş, Mahmut, Kale, Mustafa, and Çakmak, Soner

Subjects
*PRESCHOOL children, *PARENT attitudes, *BODY mass index, *QUALITATIVE research, *SOUND recordings, *SOCIAL anxiety
Abstract

Purpose: The aim of this study was to examine the attitudes and behaviors of parents with high and low social appearance anxiety levels regarding their children's social appearance. Materials and Methods: In this study, a holistic multiple case study, one of the qualitative research methods, was used. The participants of the research are 16 parents who have a child in the preschool period living in Yüreğir district of Adana province. The outlier sampling method was used to determine the participants. In the study, Social Appearance Anxiety Scale (SSAS) was used and applied to 100 participants to determine the social appearance anxiety levels of parents. The data obtained were analyzed with the IBM SPSS 25 program, and a total of 16 parents, eight of whom had the highest and the lowest scores, were determined. Interviews were conducted with the parents using the semi-structured interview form created by the researcher. The interviews were made with audio recordings and the audio recordings were converted into texts and the texts were subjected to content analysis. Results: The highest SSAS score in the participant group was 66, the lowest was 24, and the mean score was 35.71 ± 9.98. The mean age of parents with low SSAS scores is 34.75 ± 5.57. The mean age of parents with high SSAS scores is 31.62 ± 2.38. Differences were determined in the opinions of the parents about their children's social appearance, their expectations for their children's bodies, and the ideal child body definitions according to the SSAS score levels of the parents. Parents with high SSAS scores made more definitions of aesthetic appearance. In addition, it was observed that the children of parents with high SSAS scores had incompatible definitions with Body Mass Index (BMI). On the contrary, it was understood that parents with low SSAS scores do not idealize their children's bodies. In the interventions of parents with low and high SSAS scores on their children's social appearance; Differences were also found in physical activities, clothing preferences and physical appearance practices. Conclusion: While parents with low SSAS scores do not idealize their children's body, it is seen that parents with high SSAS scores make definitions regarding aesthetic appearance. In addition, it was observed that the children of parents with high SSAS scores had definitions that were incompatible with BMI. According to study, parents with high SSAS scores interfere more with their children's body appearance. They show more attitudes and behaviors in the form of eating restrictions, encouragement to action, and comparison with their peers. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

Author

Atcı, Muhammed Mustafa, primary, Geredeli, Çağlayan, additional, Ay, Seval, additional, Sakin, Abdullah, additional, Ertürk, Biray, additional, Seçmeler, Şaban, additional, Arıcı, Serdar, additional, Çekin, Ruhper, additional, Yaşar, Nurgül, additional, Can, Orçun, additional, Cihan, Şener, additional, and Gümüş, Mahmut, additional

Published
2021
Full Text
View/download PDF

45. Atypically Located Hydatid Cyst Cases: Four Unusual Case Reports.

Author

Bulut, Aziz, Bilen, Nurullah, Aytekin, Alper, Yılmaz, Latif, Özgül, Mert Kaan, Gümüş, Mahmut, Yıldız, Fahrettin, and Çoban, Sacid Abdussemet

Subjects
ECHINOCOCCOSIS, CYSTS (Pathology), HEPATIC echinococcosis, FEMUR head, ADRENAL glands, ECHINOCOCCUS
Abstract

Hydatid cysts are frequently located in liver (65-70%) and lungs (25%). The disease is usually asymptomatic when located in the extrahepatic regions. Sometimes, diagnosis can be established by observing germinative membrane, rockwater, or daughter vesicles during the operation. A 41-year-old female patient applied with the complaint of intermittent left inguinal pain. Echinococcus Indirect Hemagglutination (IHA) test was positive. In the ultrasonographic examination, a hypoechoic area was observed in the posteromedial of the left femoral head. A 56-year-old female patient, applied with the complaints of intermittent nausea, vomiting, and epigastric pain. She had a history of surgery for liver hydatid cyst 15 years ago and for lung hydatid cyst 10 years ago. IHA test of the patient was positive. The lesion involving septation and accompanied by calcifications around the cyst was reported as a hydatid cyst at dynamic CT for pancreas and upper abdominal MRI. A 22-year-old female patient applied with perianal pain complaint. Drainage was planned for the patient who had a pre-diagnosis of perianal abscess. Tissues similar to the hydatid cyst membrane were excised together with purulent fluid. The patient was diagnosed with hydatid cyst after the pathology result was reported "as compatible with hydatid cyst". A 32-year-old female patient had a non-metabolic adrenal subcapsular cyst (hydatid cyst?) in the right adrenal gland on ultrasonography performed for abdominal pain. In abdominal tomography, a "cystic mass compatible with hydatid cyst located in the adrenal gland in the upper pole of the right kidney" was reported. IHA test of the patient was negative. Hydatid cysts located in the perianal region and muscles have been reported as atypical localizations in the literature, and some of them were diagnosed as a result of preoperative clinical evaluation and radiological imaging. Some were diagnosed as a result of pathological examination after the operation. Surgical treatment is an option in suitable cases, and the definitive diagnosis can be established by pathology. Consequently, it should be considered that cystic lesions detected in the patients living in endemic regions can be extrahepatic hydatid cyst that is localized in different anatomical regions. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Author

Sezer, Ahmet, primary, Kilickap, Saadettin, additional, Gümüş, Mahmut, additional, Bondarenko, Igor, additional, Özgüroğlu, Mustafa, additional, Gogishvili, Miranda, additional, Turk, Haci M, additional, Cicin, Irfan, additional, Bentsion, Dmitry, additional, Gladkov, Oleg, additional, Clingan, Philip, additional, Sriuranpong, Virote, additional, Rizvi, Naiyer, additional, Gao, Bo, additional, Li, Siyu, additional, Lee, Sue, additional, McGuire, Kristina, additional, Chen, Chieh-I, additional, Makharadze, Tamta, additional, Paydas, Semra, additional, Nechaeva, Marina, additional, Seebach, Frank, additional, Weinreich, David M, additional, Yancopoulos, George D, additional, Gullo, Giuseppe, additional, Lowy, Israel, additional, and Rietschel, Petra, additional

Published
2021
Full Text
View/download PDF

48. Role of tumor location on high-grade serous ovarian cancer prognosis.

Author

Ay, Seval, Tataroğlu Özyükseler, Deniz, Başak, Mustafa, Dülgar, Özgecan, Arıcı, Serdar, Emre Yıldırım, Mahmut, and Gümüş, Mahmut

Subjects
OVARIAN cancer, PROGNOSTIC tests, OVERALL survival, STATISTICAL hypothesis testing, HOSPITALS
Abstract

Objectives: Ovarian cancer is associated with the highest mortality of gynecologic cancers. Epidemiological and genetic factors of ovarian cancer development are clearly defined but prognostic factors have not been adequately identified. Right and left ovarian cancers seem to act different behaviors at high-grade serous ovarian cancer (HGSOC) prognosis. The aim of this study is to explain this prognostic role of its sidedness. Material and methods: We reviewed 160 consecutive patients with Figo stage 1-3 HGSOCs and undergone surgery at two high-volume hospitals. Prognostic effects of primary tumor location onset were evaluated in terms of 5-year disease free survival and overall survival rate. Results: One hundred-sixty patients with ovarian cancer records were analyzed using the Kaplan-Meier method, that demonstrated a significant difference in the 5-year disease-free survival rates between right and left-sided cancers for all stages (44.6% vs 78.5%, p < 0.001). Also, there was significant difference in the 5-year overall survival rates between the two groups (71.1% vs 91.9%, p = 0.020). Conclusions: Tumor location within the HGSOC seems to be a compelling prognostic factor ovarian cancer. Further prospective studies are needed in order to support our hypothesis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results